Briefing
The Daily Briefing — 25 May 2026
NORML calls for renewed support in fight for cannabis justice The US advocacy organisation NORML has issued a public appeal for continued support, arguing that the fight for "justice, equity, and
United States
Federal reform, state legalisation, and the shifting American cannabis economy.
USA
Green Gold Rush: US Medical Cannabis Market on Track to Surpass $45 Billion by 2027, Q1 2026 Report Reveals
Q1 2026 data projects US medical cannabis market to exceed $45 billion by 2027, with record sales but price compression squeezing multi-state operators in mature western states.
USA
First Light in the First State: Delaware Launches Adult-Use Cannabis Sales, Becoming 25th Market
Delaware became the 25th US state to legalise adult-use cannabis sales on 15 April 2026, with three retailers opening under a social equity-focused licensing programme.
USA
Landmark Bipartisan Bill Aims to Expand Medical Cannabis Access for US Veterans
Bipartisan legislation and a $25 million VA funding push could finally allow doctors to recommend medical cannabis to veterans in legal states.
USA
SAFE Banking Act Revived in US Senate with Bipartisan Push and 280E Reform Amendment
The SAFE Banking Act has been reintroduced in the US Senate with a key Section 280E reform amendment, advancing through committee hearings with bipartisan support.
USA
FDA Unveils Long-Awaited CBD Regulatory Framework, Sparking Industry Debate
FDA releases March 2026 draft guidance on hemp-derived CBD, proposing a 20 mg daily cap and strict labelling rules for a $4B+ market.
USA
DEA Cannabis Rescheduling Hearings Begin: Historic Shift Looms as Schedule III Debate Intensifies
DEA hearings in March 2026 weigh historic move of cannabis to Schedule III, with HHS and DEA officials clashing over medical use and public health risks.